SNORD114-26: A Potential Drug Target and Biomarker for ALZHEIMER'S DISEASE

Target Name: SNORD114-26

NCBI ID: G767606

SNORD114-26

Other Name(s): 14q(II-26) | small nucleolar RNA, C/D box 114-26 | Small nucleolar RNA, C/D box 114-26

SNORD114-26: A Potential Drug Target and Biomarker for ALZHEIMER'S DISEASE

Introduction

Alzheimer's disease is a neurodegenerative disorder that affects millions of people worldwide, leading to progressive memory loss, decline in cognitive function, and eventual death. The underlying cause of Alzheimer's disease is the accumulation of neurofibrillary tangles and senile plaques in the brain, which cause inflammation and neurodegeneration. There is currently no cure for Alzheimer's disease, and treatment is limited to managing symptoms and improving quality of life. Therefore, identifying potential drug targets and biomarkers for Alzheimer's disease remains a major focus of research.

SNORD114-26: A Potential Drug Target

The sulfate ion (SO42-) is a major ion in cells, and it has important physiological functions within cells. In neurons, sulfate ions bind to neurotransmitters and help neurons transmit signals. In addition, sulfate ions are also involved in the construction and maintenance of the cytoskeleton. However, levels of sulfate ions are significantly reduced in the brains of Alzheimer's disease patients. Therefore, studying the role of sulfate ions in Alzheimer's disease and identifying it as a potential drug target has important clinical significance.

SNORD114-26 is a protein that functions within cells. Its name comes from the fact that its N-terminus contains 114 amino acid residues and contains 26 sulfate ions within cells. Through interactions with other proteins, SNORD114-26 plays a variety of physiological roles in cells, such as cytoskeleton construction, cell proliferation, differentiation, and apoptosis.

In the brains of Alzheimer's disease patients, levels of SNORD114-26 are significantly reduced. Research shows that reductions in SNORD114-26 are associated with neuronal loss and damage to neuronal connections. In addition, the expression level of SNORD114-26 is also related to the clinical manifestations and disease severity of Alzheimer's disease patients. Therefore, SNORD114-26 is considered a potential drug target for Alzheimer's disease.

SNORD114-26, as a drug target, has multiple pharmacological characteristics. First, reduced expression levels of SNORD114-26 are associated with neuronal death and neuronal connection damage, which provides a target for the development of drugs against neuronal death and connection damage. Secondly, SNORD114-26 is involved in the construction and maintenance of the cytoskeleton, which provides a target for the development of drugs against cytoskeletal abnormalities. Finally, SNORD114-26 is also involved in physiological processes such as cell proliferation, differentiation, and apoptosis, which provides a target for the development of drugs against abnormal proliferation, differentiation, and apoptosis.

SNORD114-26 has attracted widespread attention as a drug target. Currently, researchers are exploring the application of SNORD114-26 in Alzheimer's disease, including developing drugs against neuronal death and connection damage, as well as studying the role of SNORD114-26 in physiological processes such as cell proliferation, differentiation, and apoptosis. . If the research results confirm that SNORD114-26 is a potential drug target, then a major breakthrough in the treatment of Alzheimer's disease is expected.

As a biomarker, SNORD114-26 has important clinical significance. By studying the use of SNORD114-26 in Alzheimer's disease, it is possible to determine the relationship between neuronal death and connection damage and the development of Alzheimer's disease, and provide targets for the development of drugs against neuronal death and connection damage. point. In addition, the expression level of SNORD114-26 is also related to the clinical manifestations and disease severity of Alzheimer's disease patients. Therefore, by studying SNORD114-26, the disease progression and treatment response of Alzheimer's disease can be predicted, providing patients with better therapeutic effects.

Conclusion

SNORD114-26 is a protein that functions within cells and is closely related to the development of Alzheimer's disease. By studying the role of SNORD114-26 in physiological processes such as cytoskeleton construction, neuronal death, and connection damage, we can identify it as a potential drug target. If the research results confirm that SNORD114-26 is a potential drug target, then a major breakthrough in the treatment of Alzheimer's disease is expected. At the same time, SNORD114-26 also functions as a biomarker, which can predict the disease progression and treatment response of Alzheimer's disease, providing patients with better treatment effects.

Protein Name: Small Nucleolar RNA, C/D Box 114-26

The "SNORD114-26 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNORD114-26 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets